Dr Edward Garon speaks to ecancer about the role of immune checkpoint inhibitors in EGFR mutant lung cancer patients.

He explains that to date there has been great difficulty in integrating immune checkpoint inhibitors into therapy for patients who have EGFR mutations.

Dr Garon discusses a number of studies that have investigated the therapy in this setting and believes that this is an area where there isn't an ideal solution as of yet.

This programme has been supported by an unrestricted educational grant from Bristol Myers Squibb.